Cargando…

Dog-Assisted Therapy for Children and Adolescents With Fetal Alcohol Spectrum Disorders a Randomized Controlled Pilot Study

OBJECTIVE: The rationale of this study was to evaluate the efficacy of dog-assisted therapy (DAT) combined with pharmacological treatment in children and adolescents with fetal alcohol spectrum disorder (FASD). METHOD: We conducted a randomized, rater-blinded, controlled pilot trial in a cohort of 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Vidal, Raquel, Vidal, Laura, Ristol, Francesc, Domènec, Eva, Segú, Marta, Vico, Cristina, Gomez-Barros, Núria, Ramos-Quiroga, Josep Antoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264372/
https://www.ncbi.nlm.nih.gov/pubmed/32528389
http://dx.doi.org/10.3389/fpsyg.2020.01080
Descripción
Sumario:OBJECTIVE: The rationale of this study was to evaluate the efficacy of dog-assisted therapy (DAT) combined with pharmacological treatment in children and adolescents with fetal alcohol spectrum disorder (FASD). METHOD: We conducted a randomized, rater-blinded, controlled pilot trial in a cohort of 33 children and adolescents with FASD. Participants were randomly assigned either to DAT group (n = 17) or Treatment as Usual (TAU control group) (n = 16). RESULTS: Of the initial 39 participants enrolled, 33 completed treatment. A mixed-effects model analysis revealed that participants who were assigned to the DAT group experienced significantly improvements on social skills (SSIS-P social skills: p = 0.02, d = 0.8), reductions on externalizing symptoms (CBCL externalizing: p = 0.03; d = 0.56), and lower scores on FASD severity (CGI-S clinician: p = 0.001, d = 0.5). CONCLUSION: DAT is a promising adjunctive treatment for children and adolescents with FASD. CLINICAL TRIAL REGISTRATION: Dog-assisted therapy for children and adolescents with fetal alcohol spectrum disorders: a randomized controlled pilot study; http://clinicaltrials.gov/, identifier NCT04038164.